

2018

# Antibiotic Resistance Rates for *Pseudomonas aeruginosa* Clinical Respiratory and Bloodstream Isolates Among the Veterans Affairs Healthcare System from 2009 to 2013

Haley J. Appaneal  
*University of Rhode Island*

Aisling R. Caffrey  
*University of Rhode Island*, [aisling\\_caffrey@uri.edu](mailto:aisling_caffrey@uri.edu)

Follow this and additional works at: [https://digitalcommons.uri.edu/php\\_facpubs](https://digitalcommons.uri.edu/php_facpubs)

**The University of Rhode Island Faculty have made this article openly available.  
Please let us know how Open Access to this research benefits you.**

This is a pre-publication author manuscript of the final, published article.

## Terms of Use

This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our [Terms of Use](#).

## Citation/Publisher Attribution

Appaneal HJ, Caffrey AR, Jiang L, Dosa D, Mermel LA, LaPlante KL. *Diagn Microbiol Infect Dis*. 2018 Apr;90(4):311-315. doi: 10.1016/j.diagmicrobio.2017.11.022  
Available at: <https://doi.org/10.1016/j.diagmicrobio.2017.11.022>

This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact [digitalcommons@etal.uri.edu](mailto:digitalcommons@etal.uri.edu).

---

**Authors**

Haley J. Appaneal, Aisling R. Caffrey, Lan Jiang, David Dosa, Leonard A. Mermel, and Kerry L. LaPlante

1 **Antibiotic Resistance Rates for *Pseudomonas aeruginosa* Clinical Respiratory and**  
2 **Bloodstream Isolates Among the Veterans Affairs Healthcare System from 2009 to 2013**

3 Haley J. Appaneal<sup>1,2,3\*</sup>, Aisling R. Caffrey<sup>1,2,3,4</sup>, Lan Jiang<sup>3</sup>, David Dosa<sup>3,5</sup>, Leonard A. Mermel<sup>2,6,7</sup>,  
4 and Kerry L. LaPlante<sup>1,2,3,7</sup>

5 1. Veterans Affairs Medical Center, Rhode Island Infectious Diseases Research Program,  
6 Providence, RI

7 2. University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy,  
8 Kingston, RI

9 3. Veterans Affairs Medical Center, Center of Innovation in Long Term Services and Supports,  
10 Providence, RI

11 4. Brown University School of Public Health, Providence, RI

12 5. Center for Gerontology and HealthCare Research, Brown University School of Public Health,  
13 Providence, RI, United States

14 6. Department of Epidemiology and Infection Control, Rhode Island Hospital, Providence, RI,  
15 United States

16 7. Warren Alpert Medical School of Brown University, Division of Infectious Diseases,  
17 Providence, RI

18 **Running title:** *Pseudomonas aeruginosa* Resistance

19 **Abstract word count:** 150

20 **Body of the text word count:** 1,665

21 **Keywords:** *Pseudomonas aeruginosa*, resistance, multidrug-resistance

22 \*Corresponding Author

23 Haley J. Appaneal, Pharm.D., Research Health Science Specialist, Providence Veterans Affairs  
24 Medical Center, 830 Chalkstone Ave, Providence, RI 02908, 401-273-7100 ext 4150 (office);

25 [haley.morrill@va.gov](mailto:haley.morrill@va.gov)

26

1 **Abstract**

2 *Pseudomonas aeruginosa* is a major cause of healthcare-associated infections and resistance  
3 among isolates is an increasing burden. The study purpose was to describe national resistance  
4 rates for clinical *P. aeruginosa* respiratory and bloodstream cultures and the prevalence of  
5 multidrug-resistant (MDR) *P. aeruginosa* within the Veterans Affairs (VA). MDR was defined as  
6 non-susceptibility to at least one drug in at least 3 of the following 5 categories: carbapenems,  
7 extended-spectrum cephalosporins, aminoglycosides, and piperacillin/tazobactam. We reviewed  
8 24,562 *P. aeruginosa* respiratory and bloodstream isolates across 126 VA facilities between 2009  
9 to 2013. Most isolates were collected from inpatient settings (82%). Resistance was highest in  
10 fluoroquinolones (33%) and exceeded 20% for all classes assessed (carbapenems, extended-  
11 spectrum cephalosporins, aminoglycosides, and piperacillin/tazobactam). Resistance was higher  
12 in inpatient settings and in respiratory isolates. Prevalence of MDR was 20% overall (22% for  
13 inpatient isolates, 11% outpatient, 21% respiratory, 17% bloodstream). Our findings are  
14 consistent with previous surveillance reports

15 .

1 **Body of the Text**

2 *Introduction*

3 *Pseudomonas aeruginosa* is a major cause of healthcare-associated infections.(1) *P. aeruginosa*  
4 is a leading cause of severe Gram-negative infections, including pneumonia and bloodstream  
5 infections, which are associated with high mortality rates.(2, 3) Antimicrobial resistance and  
6 multidrug-resistance (MDR) among *P. aeruginosa* isolates collected from hospitalized patients  
7 are increasing and threaten the appropriate treatment of patients with severe infections.(4, 5) *P.*  
8 *aeruginosa* is also an important cause of community-acquired pneumonia in patients with  
9 underlying lung disease, alcoholism and compromised immune function.(6-8) However,  
10 surveillance of isolates from the community is less frequent than from healthcare settings and  
11 nationwide resistance rates in community setting are less well understood.

12  
13 The Veterans Affairs (VA) is the largest integrated healthcare system in the United States (US),  
14 providing care to approximately 9 million Veterans in 140 medical centers and 1200 outpatient  
15 clinics. Clinical antimicrobial susceptibility data from VA electronic datasets support a nationwide  
16 description of *P. aeruginosa* resistance.(9) The aim of this study was to assess national antibiotic  
17 resistance rates for clinical *P. aeruginosa* respiratory and bloodstream cultures, as well as  
18 determine the prevalence of MDR *P. aeruginosa* in the VA system.

19  
20 *Methods*

21 We evaluated antimicrobial susceptibility from all VA hospitals, long-term care units and outpatient  
22 facilities in the United States.(9) We included all *P. aeruginosa* blood and respiratory clinical  
23 cultures collected between January 1, 2009 to December 31, 2013 from patients aged 18 years  
24 or older.

25

1 We defined antibiotic resistance per the CDC Antibiotic Resistance Patient Safety Atlas  
2 Phenotype Definitions.(10) We included the first isolate per person, per facility, per month.(10)  
3 Antibiotic susceptibility was based on the reported microbiology results of the clinical culture. As  
4 microbiology practices and susceptibility breakpoints are not standardized throughout the VA  
5 system, we applied the 2014 Clinical Laboratory Standards Institute (CLSI) breakpoints to  
6 determine non-susceptibility where numeric minimum inhibitory concentrations (MIC) data were  
7 available.(11) Where MIC values were not available, we used the reported textual interpretation  
8 (i.e., resistant [R], intermediate [I], or susceptible [S]).(12) In cases of duplicate (same patient,  
9 same isolate, same day), yet conflicting antimicrobial susceptibility results, we included the most  
10 resistant result (i.e., R > I > S).(12)

11  
12 We grouped individual antibiotic agents into five categories as follows: extended-spectrum  
13 cephalosporins (ceftazidime and cefepime); fluoroquinolones (levofloxacin and ciprofloxacin);  
14 aminoglycosides (amikacin, gentamicin, and tobramycin); carbapenems (imipenem, meropenem,  
15 and doripenem), and piperacillin/tazobactam (piperacillin and piperacillin/tazobactam).(10)  
16 Resistance was defined as an isolate that was not susceptible, thus either intermediate or  
17 resistant, to at least one drug in that category.(10) Multidrug-resistance (MDR) was defined as  
18 non-susceptibility to at least one drug in at least 3 of the 5 categories (extended-spectrum  
19 cephalosporins, aminoglycosides, carbapenems, and piperacillin/tazobactam).(10)

20  
21 We presented summary rates of antibiotic resistance for each of the five antibiotic categories  
22 assessed and prevalence of MDR among *P. aeruginosa* isolates. Antibiotic resistance for each  
23 antibiotic category was calculated as the number of non-susceptible isolates divided by the total  
24 number of isolates tested. Prevalence of MDR was calculated as the number of MDR isolates  
25 divided by the total number of isolates tested. We presented overall rates of antibiotic resistance

1 and MDR over the entire study period, and presented rates by treatment setting, source, and CDC  
2 region. All analyses will be performed with SAS (SAS, Cary, NC, Version 9.2).

3  
4 *Results*

5 We identified 24,562 *P. aeruginosa* isolates from 126 VA facilities over the 5-year study period;  
6 82% were from inpatient settings. Most isolates were obtained from white (72%), male (97%),  
7 Veterans 65 years and older (59%). Resistance was highest for fluoroquinolones (33%) and  
8 lowest for the piperacillin class (piperacillin/tazobactam and piperacillin, 21%; Table 1).  
9 Resistance to carbapenems, extended-spectrum cephalosporins, and aminoglycosides was 24-  
10 25%. Resistance was higher in inpatient settings (Table 1) and in respiratory isolates (Table 2).  
11 Prevalence of MDR was 20% overall (22% and 11% for inpatient and outpatient settings,  
12 respectively; and 21% and 17% for respiratory and bloodstream isolates, respectively).

13  
14 Among inpatient cultures, resistance rates were highest in the Pacific region (fluoroquinolones  
15 42%, carbapenems 35%, MDR 30%) and lowest in the Mountain (fluoroquinolones 27%,  
16 carbapenems 17%, MDR 14%) and New England regions (fluoroquinolones 27%, piperacillin  
17 class 17%, MDR 16%) (Figure 1). Outpatient resistance rates were highest in the Mid-Atlantic  
18 region (fluoroquinolones 31%, carbapenems 22%, MDR 21%) and lowest in the New England  
19 (fluoroquinolones 20%, carbapenems 10%, MDR 6%) and West South Central regions  
20 (fluoroquinolones 17%, carbapenems 11%, MDR 7%) (Figure 2).

21  
22 *Discussion*

23 Treatment of *P. aeruginosa* infections are challenging due to intrinsic resistance and ability to  
24 develop resistance to multiple antimicrobial classes.(13, 14) These features limit treatment  
25 options and complicate selection of appropriate initial antibiotic treatment, which can have  
26 devastating consequences on patient outcomes.(14, 15) We observed rates of resistance in

1 excess of 20% for all antimicrobial classes assessed. Our findings are similar to previous  
2 surveillance reports, and in some cases, resistance was higher in our study.(4, 5, 13) The most  
3 recent study of 7,452 *P. aeruginosa* isolates from 79 US medical centers between 2012 to 2014  
4 demonstrated non-susceptibility of 20% for piperacillin-tazobactam, 18% for meropenem, and  
5 16% for ceftazidime, compared to our findings of 24% resistance for piperacillin-tazobactam and  
6 piperacillin, 27% for carbapenem, and 27% for extended-spectrum cephalosporins.(13)

7  
8 Prior surveillance data suggests a trend towards stabilized or decreased antimicrobial resistance  
9 to several agents among *P. aeruginosa* isolates in the US.(13, 16) Recent data from the VA  
10 system has demonstrated this trend in decreased antimicrobial resistance among *P. aeruginosa*  
11 isolates.(17) We observed similar resistance rates among bloodstream isolates to those  
12 previously reported. We also found higher resistance rates among nosocomial isolates and  
13 variations in resistance rates by CDC region.(17)

14  
15 Overall, we demonstrated high rates of MDR among *P. aeruginosa* isolates (20%), with higher  
16 rates in the inpatient vs. outpatient setting (22% vs. 11% outpatient) and pulmonary vs. blood  
17 source (21% vs. 17% blood). National surveillance data from 2000 to 2009, including 205,526 *P.*  
18 *aeruginosa* isolates from pneumonia and bloodstream infections, demonstrated prevalence rates  
19 of MDR among *P. aeruginosa* isolates similar to our findings (22% for pneumonia; 15% for  
20 bloodstream infections).(4) Among bloodstream isolates in a recent VA study, there was a lower  
21 rate of MDR than we had observed.(17) Differences in methods used to define MDR likely explain  
22 variations in reported MDR rates. While we used the CDC Patient Atlas MDR definitions requiring  
23 non-susceptibility to at least one antibiotic in at least 3 different classes, the previous study  
24 required resistance to all antibiotics tested in at least 3 different classes.(17)

25  
26 Finally, our results from the outpatient setting are noteworthy. None of the antimicrobial classes



1 assessed provided greater than 10% anti-pseudomonal coverage and rates of MDR were 11%  
2 nationally (Table 1), exceeding 20% in the Mid Atlantic region (Figure 2). Inappropriate initial  
3 empiric antimicrobial treatment is thus an important concern in the treatment of community-onset  
4 *P. aeruginosa* infections. Inappropriate initial empiric antimicrobial treatment is common  
5 inpatients with community-acquired *P. aeruginosa* bloodstream infections and those with  
6 pneumonia and it is associated with greater mortality.(18, 19) While combination therapy remains  
7 controversial, it may be important approach to minimize inappropriate initial therapy, especially in  
8 regions with the highest resistance rates.

9  
10 Our findings add to previous work, highlighting antibiotic resistance among *P. aeruginosa* isolates  
11 nationally. We demonstrated that resistance to five key and commonly used antimicrobial classes  
12 was high despite treatment setting, culture source, and region. Due to the poor outcomes  
13 associated with inappropriate treatment of severe *P. aeruginosa* isolates, facilities should  
14 consider developing treatment pathways or policies, which potentially include use of combination  
15 therapy and/or newer antimicrobial options, for infections in which MDR organisms are suspected.  
16 Additionally, knowledge of specific risk factors for resistant and MDR *P. aeruginosa* isolates would  
17 be important to help clinicians better care for patients with infections due to resistant pathogens,  
18 and is an important next step to this work. Finally, antimicrobial stewardship programs are  
19 mandated in the acute care setting in the VA, however increased efforts in the outpatient setting  
20 are warranted and urgently needed.(20) Increased assistance with antibiotic selection could help  
21 to manage these difficult to treat infections due resistant *P. aeruginosa* isolates and potentially  
22 improve patient outcomes.

23  
24 There are limitations to this observational, cross-sectional work. The inclusion of all positive *P.*  
25 *aeruginosa* respiratory and blood cultures enabled us to describe ecological resistance in the VA  
26 system, however, we did not distinguish between colonization from true infection. Additionally,

1 there is the potential for misclassification of community-acquired isolates, as we did not assess  
2 healthcare contact prior to outpatient culture date. Another limitation is that our definition of  
3 resistance was based on non-susceptibility. Therefore, isolates that were intermediate met our  
4 definition of resistance, and as such we may have overestimated true resistance. However, our  
5 definitions are consistent with those used by the CDC Patient Safety Atlas.(10) There is  
6 heterogeneity among microbiology laboratories in the VA system and different testing methods  
7 among labs may have impacted our findings. We applied CLSI susceptibility breakpoints where  
8 MIC data was available, however MIC data was not available for all isolates. In such cases we  
9 had to rely on the interpretation as provided by the testing microbiology laboratory. Finally, the  
10 generalizability of the study population and results are limited to the VA, a fully integrated  
11 healthcare system consisting of largely older, white male patients.

12

13 In summary, among nearly 25,000 clinical *P. aeruginosa* respiratory and bloodstream isolates,  
14 resistance to five key and commonly used antimicrobial classes (fluoroquinolones, carbapenems,  
15 extended-spectrum cephalosporins, aminoglycosides, and piperacillin group) exceeded 20% and  
16 20% of isolates were MDR. Resistance was higher among isolates collected from the inpatient  
17 versus outpatient setting and from a respiratory source.

18

1 **Acknowledgements.**

2 The views expressed are those of the authors and do not necessarily reflect the position or policy  
3 of the United States Department of Veterans Affairs. This material is based upon work supported,  
4 in part, by the Office of Research and Development, Department of Veterans Affairs.

5

6 *Conflict of interest.*

7 Haley J. Morrill is supported in part by a Career Development Award, Department of Veterans  
8 Affairs, and has received research funding from Merck (Cubist).

9 Aisling R. Caffrey has received research funding from Pfizer Inc and Merck (Cubist), and The  
10 Medicines Company.

11 Lan Jiang has no conflicts.

12 David Dosa is a Veteran's Affairs government employee. He has received research funding  
13 through the VA, The West Foundation, and National Institutes of Aging.

14 Leonard A. Mermel has served as a consultant for The Medicines Company and has received  
15 research support from BARD.

16 Kerry L. LaPlante has received research funding, or acted as an advisor or consultant for  
17 BARD/Davol, Merck (Cubist), Ocean Spray, Allergan, Pfizer Inc, and The Medicines Company.

18

## References

- 1  
2  
3 1. **Gaynes R, Edwards JR, National Nosocomial Infections Surveillance S.** 2005.  
4 Overview of nosocomial infections caused by gram-negative bacilli. *Clin Infect Dis*  
5 **41:848-854.**
- 6 2. **Hattemer A, Hauser A, Diaz M, Scheetz M, Shah N, Allen JP, Porhomayon J, El-**  
7 **Solh AA.** 2013. Bacterial and clinical characteristics of health care- and community-  
8 acquired bloodstream infections due to *Pseudomonas aeruginosa*. *Antimicrob Agents*  
9 *Chemother* **57:3969-3975.**
- 10 3. **Rodrigo-Troyano A, Sibila O.** 2017. The respiratory threat posed by multidrug resistant  
11 Gram-negative bacteria. *Respirology* doi:10.1111/resp.13115.
- 12 4. **Zilberberg MD, Shorr AF.** 2013. Prevalence of multidrug-resistant *Pseudomonas*  
13 *aeruginosa* and carbapenem-resistant Enterobacteriaceae among specimens from  
14 hospitalized patients with pneumonia and bloodstream infections in the United States  
15 from 2000 to 2009. *J Hosp Med* **8:559-563.**
- 16 5. **Sader HS, Farrell DJ, Flamm RK, Jones RN.** 2014. Antimicrobial susceptibility of  
17 Gram-negative organisms isolated from patients hospitalised with pneumonia in US and  
18 European hospitals: results from the SENTRY Antimicrobial Surveillance Program,  
19 2009-2012. *Int J Antimicrob Agents* **43:328-334.**
- 20 6. **Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A.** 2008. A comparative study  
21 of community-acquired pneumonia patients admitted to the ward and the ICU. *Chest*  
22 **133:610-617.**
- 23 7. **Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A.**  
24 2002. Community-acquired pneumonia due to gram-negative bacteria and  
25 *pseudomonas aeruginosa*: incidence, risk, and prognosis. *Arch Intern Med* **162:1849-**  
26 **1858.**
- 27 8. **Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, Puig de la**  
28 **Bellacasa J, Menendez R, Mensa J, Torres A.** 2015. Risk factors associated with  
29 potentially antibiotic-resistant pathogens in community-acquired pneumonia. *Ann Am*  
30 *Thorac Soc* **12:153-160.**
- 31 9. **Department of Veterans Affairs.** Department of Veterans Affairs Statistics at a Glance.  
32 [http://www.va.gov/vetdata/docs/Quickfacts/Stats\\_at\\_a\\_glance\\_08\\_27\\_15.pdf](http://www.va.gov/vetdata/docs/Quickfacts/Stats_at_a_glance_08_27_15.pdf) Last  
33 updated: 06/30/2015. Accessed: 03/17/2016.
- 34 10. **Centers for Disease Control and Prevention.** Antibiotic Resistance Patient Safety  
35 Atlas. Phenotype Definitions. Accessed April 13, 2016. Available at  
36 "[http://gis.cdc.gov/grasp/PSA/Downloads/ARPatientSafetyAtlas-](http://gis.cdc.gov/grasp/PSA/Downloads/ARPatientSafetyAtlas-PhenotypeDefinitions.pdf)  
37 [PhenotypeDefinitions.pdf](http://gis.cdc.gov/grasp/PSA/Downloads/ARPatientSafetyAtlas-PhenotypeDefinitions.pdf)".
- 38 11. **Clinical Laboratory Standards Institute (CLSI).** January 2015. CLSI document M100-  
39 S25, . Performace Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth  
40 Informational Supplement.

- 1 12. **Centers for Disease Control and Prevention (CDC). National Healthcare Safety**  
2 **Network (NHSN).** January 2014. Available at:  
3 <http://www.cdc.gov/nhsn/PDFs/pscManual/11pscAURcurrent.pdf> (accessed November  
4 2014). Antimicrobial Use and Resistance (AUR) Module.
- 5 13. **Sader HS, Huband MD, Castanheira M, Flamm RK.** 2017. *Pseudomonas aeruginosa*  
6 Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International  
7 Network for Optimal Resistance Monitoring Program in the United States. *Antimicrob*  
8 *Agents Chemother* **61**.
- 9 14. **Lister PD, Wolter DJ, Hanson ND.** 2009. Antibacterial-resistant *Pseudomonas*  
10 *aeruginosa*: clinical impact and complex regulation of chromosomally encoded  
11 resistance mechanisms. *Clin Microbiol Rev* **22**:582-610.
- 12 15. **Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH.** 2005.  
13 *Pseudomonas aeruginosa* bloodstream infection: importance of appropriate initial  
14 antimicrobial treatment. *Antimicrob Agents Chemother* **49**:1306-1311.
- 15 16. **Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR,**  
16 **Sievert DM.** 2016. Antimicrobial-Resistant Pathogens Associated With Healthcare-  
17 Associated Infections: Summary of Data Reported to the National Healthcare Safety  
18 Network at the Centers for Disease Control and Prevention, 2011-2014. *Infect Control*  
19 *Hosp Epidemiol* doi:10.1017/ice.2016.174:1-14.
- 20 17. **Gentry CA, Williams RJ, 2nd.** 2015. Increased antimicrobial susceptibility rates for  
21 *Pseudomonas aeruginosa* bloodstream isolates across the Veterans Affairs Healthcare  
22 System. *Diagn Microbiol Infect Dis* **82**:215-221.
- 23 18. **Cheong HS, Kang CI, Wi YM, Ko KS, Chung DR, Lee NY, Song JH, Peck KR.** 2008.  
24 Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with  
25 community-onset *Pseudomonas aeruginosa* bacteraemia. *Eur J Clin Microbiol Infect Dis*  
26 **27**:1219-1225.
- 27 19. **Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J,**  
28 **Niederman MS, Torres A.** 2016. Community-Acquired Pneumonia Due to Multidrug-  
29 and Non-Multidrug-Resistant *Pseudomonas aeruginosa*. *Chest* **150**:415-425.
- 30 20. **Department of Veterans Affairs.** January 2014. Available at:  
31 [http://www.va.gov/vhapublications/ViewPublication.asp?pub\\_ID=2964](http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2964) (accessed May  
32 2014). Antimicrobial Stewardship Programs (ASP) (VHA Directive 1031).  
33

1 **Table 1. Antibiotic Resistance Rates for *Pseudomonas aeruginosa* Respiratory and Blood**  
 2 **Cultures among Veterans Affairs Inpatient and Outpatient Facilities by Treatment Setting**  
 3 **from 2009 to 2013**

Antibiotic Category	Setting		
	Overall	Inpatient	Outpatient
Fluoroquinolones	33 (23,938)	36 (19,634)	23 (4,304)
Carbapenems	25 (21,176)	27 (17,424)	15 (3,752)
Extended-spectrum cephalosporins	25 (24,068)	27 (19,758)	15 (4,310)
Aminoglycosides	24 (24,514)	25 (20,094)	21 (4,420)
Piperacillin/ piperacillin/tazobactam	21 (21,529)	24 (17,741)	10 (3,788)
MDR per CDC definitions	20 (24,562)	22 (20,134)	11 (4,428)
<b>Total Number of Isolates</b>	24,562	20,134	4,428

4 CDC= Centers for Disease Control and Prevention; MDR= Multidrug resistant  
 5 Data are % non-susceptible (number of isolates tested)

6  
 7 Extended-spectrum cephalosporins category included ceftazidime and cefepime.  
 8 Fluoroquinolones category included levofloxacin and ciprofloxacin.  
 9 Aminoglycosides category included amikacin, gentamicin, and tobramycin.  
 10 Carbapenems category included imipenem, meropenem, and doripenem.  
 11 Piperacillins included piperacillin and piperacillin/tazobactam.  
 12 CDC MDR was defined as non-susceptibility to at least one agent in at least three of the  
 13 following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins,  
 14 fluoroquinolones, and piperacillins.  
 15

1 **Table 2. *Pseudomonas aeruginosa* Antibiotic Resistance Rates for Respiratory and Blood**  
 2 **Cultures among Veterans Affairs Facilities Nationally by Culture Source from 2009 to**  
 3 **2013**

Antibiotic Category	Source		
	Overall	Lung	Blood
Fluoroquinolones	33 (23,938)	34 (20,493)	28 (3,445)
Carbapenems	25 (21,176)	25 (18,089)	20.8 (3,087)
Extended-spectrum cephalosporins	25 (24,068)	25 (20,594)	21 (3,474)
Aminoglycosides	24 (24,514)	25 (20,988)	18 (3,526)
Piperacillins	21 (21,529)	22 (18,416)	18 (3,113)
MDR per CDC definitions	20 (24,562)	21 (21,031)	17 (3,531)
<b>Total Number of Isolates</b>	24,562	21,031	3,531

4 CDC= Centers for Disease Control and Prevention; MDR= Multidrug resistant  
 5 Data are % non-susceptible (number of isolates tested)

- 6
- 7 Extended-spectrum cephalosporins category included ceftazidime and cefepime.  
 8 Fluoroquinolones category included levofloxacin and ciprofloxacin.  
 9 Aminoglycosides category included amikacin, gentamicin, and tobramycin.  
 10 Carbapenems category included imipenem, meropenem, and doripenem.  
 11 Piperacillins included piperacillin and piperacillin/tazobactam.  
 12 CDC MDR was defined as non-susceptibility to at least one agent in at least three of the  
 13 following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins,  
 14 fluoroquinolones, and piperacillins.  
 15

1 **Figure 1. *Pseudomonas aeruginosa* Antibiotic Resistance Among Veterans Affairs**  
2 **Inpatient Facilities by CDC Region**

3  
4  
5

6 AMG= Aminoglycosides; CDC= Centers for Disease Control and Prevention; E N Central= East  
7 North Central Region; E S Central= East South Central Region; ES Ceph= Extended-spectrum  
8 cephalosporin; FQ= Fluoroquinolone; MDR= Multidrug resistant; Mid Atlantic= Middle Atlantic  
9 Region; Mountain=Mountain Region; New England= New England Region; Pacific= Pacific  
10 Region; PIP= Piperacillins; S Atlantic= South Atlantic Region; W N Central= West North Central  
11 Region; W S Central= West South Central Region

12

13 Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested  
14 for every isolate tested.

15

16 Extended-spectrum cephalosporins category included ceftazidime and cefepime.  
17 Fluoroquinolones category included levofloxacin and ciprofloxacin.  
18 Aminoglycosides category included amikacin, gentamicin, and tobramycin.  
19 Carbapenems category included imipenem, meropenem, and doripenem.  
20 Piperacillins included piperacillin and piperacillin/tazobactam.  
21 CDC MDR was defined as non-susceptibility to at least one agent in at least three of the  
22 following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins,  
23 fluoroquinolones, and piperacillins.  
24



1 **Figure 2. *Pseudomonas aeruginosa* Antibiotic Resistance Among Veterans Affairs**  
2 **Outpatient Facilities by CDC Region**

3  
4  
5

6 AMG= Aminoglycosides; CDC= Centers for Disease Control and Prevention; E N Central= East  
7 North Central Region; E S Central= East South Central Region; ES Ceph= Extended-spectrum  
8 cephalosporin; FQ= Fluoroquinolone; MDR= Multidrug resistant; Mid Atlantic= Middle Atlantic  
9 Region; Mountain=Mountain Region; New England= New England Region; Pacific= Pacific  
10 Region; PIP= Piperacillins; S Atlantic= South Atlantic Region; W N Central= West North Central  
11 Region; W S Central= West South Central Region

12

13 Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested  
14 for every isolate tested.

15

16 Extended-spectrum cephalosporins category included ceftazidime and cefepime.  
17 Fluoroquinolones category included levofloxacin and ciprofloxacin.  
18 Aminoglycosides category included amikacin, gentamicin, and tobramycin.  
19 Carbapenems category included imipenem, meropenem, and doripenem.  
20 Piperacillins included piperacillin and piperacillin/tazobactam.  
21 CDC MDR was defined as non-susceptibility to at least one agent in at least three of the  
22 following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins,  
23 fluoroquinolones, and piperacillins.

24